TCR2 Therapeutics Inc.
TCRR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $98,643 | $77,239 | $51,980 | $37,488 |
| G&A Expenses | $24,439 | $22,503 | $16,720 | $13,894 |
| SG&A Expenses | $24,439 | $22,503 | $16,720 | $13,894 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $123,082 | $99,742 | $68,700 | $51,382 |
| Operating Income | -$153,499 | -$99,742 | -$68,700 | -$51,382 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,938 | $224 | $1,737 | $3,885 |
| Pre-Tax Income | -$151,561 | -$99,518 | -$66,963 | -$47,497 |
| Tax Expense | $261 | $289 | $161 | $102 |
| Net Income | -$151,822 | -$99,807 | -$67,124 | -$47,599 |
| % Margin | – | – | – | – |
| EPS | -3.93 | -2.63 | -2.4 | -2.26 |
| % Growth | -49.4% | -9.6% | -6.2% | – |
| EPS Diluted | -3.93 | -2.63 | -2.4 | -2.26 |
| Weighted Avg Shares Out | 38,628 | 37,936 | 27,991 | 21,104 |
| Weighted Avg Shares Out Dil | 38,628 | 37,936 | 27,991 | 21,104 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,938 | $224 | $1,737 | $0 |
| Interest Expense | $58,896 | $0 | $0 | $0 |
| Depreciation & Amortization | $63,880 | $2,827 | $1,592 | $862 |
| EBITDA | -$89,619 | -$96,915 | -$67,108 | -$50,520 |
| % Margin | – | – | – | – |